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Abstract 
Background: Abdominal pain is a frequent symptom in patients with inflammatory bowel disease (IBD) including 
Crohn’s disease (CD) and ulcerative colitis (UC). Pain can result from ongoing inflammation or functional disorders imi-
tating irritable bowel syndrome (IBS). Several single-nucleotide polymorphisms (SNPs) have been associated with IBS. 
However, the impact of IBS genetics on the clinical course of IBD, especially pain levels of patients remains unclear.
Methods: Data of 857 UC and 1206 CD patients from the Swiss IBD Cohort Study were analysed. We tested the asso-
ciation of the maximum of the abdominal pain item of disease activity indices in UC and CD over the study period 
with 16 IBS-associated SNPs, using multivariate ANOVA models.
Results: In UC patients, the SNPs rs1042713 (located on the ADRB2 gene) and rs4663866 (close to the HES6 gene) 
were associated with higher abdominal pain levels (P = 0.044; P = 0.037, respectively). Abdominal pain was not associ-
ated with any markers of patient management in a model adjusted for confounders. In CD patients, higher levels of 
abdominal pain correlated with the number of physician contacts (P < 10–15), examinations (P < 10–12), medical thera-
pies (P = 0.023) and weeks of hospitalisation (P = 0.0013) in a multivariate model.
Conclusions: We detected an association between maximal abdominal pain in UC patients and two IBS-associated 
SNPs. Abdominal pain levels had a pronounced impact on diagnostic and therapeutic procedures in CD but not in UC 
patients.
Keywords: Single-nucleotide polymorphisms, Abdominal pain, Inflammatory bowel disease, Ulcerative colitis, 
Crohn’s disease, Irritable bowel syndrome
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Background
Inflammatory bowel disease (IBD) comprise inflamma-
tory conditions of the intestinal tract including Crohn’s 
disease (CD) and ulcerative colitis (UC). The clini-
cal course of IBD is variable, ranging from very mild to 
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severe and life-threatening disease or complications [1]. 
Identification of reliable predictors for the clinical course 
of IBD would strongly improve patient management.
Genetic predisposition plays a prominent role in IBD 
pathogenesis. Genome wide association studies (GWAS) 
identified more than 240 single-nucleotide polymor-
phisms (SNPs) associated with the risk for IBD [2–4]. 
However, in an extensive analysis, even the combined 
genetic information was largely unable to predict the 
clinical course of IBD [5]. Therefore, it remains unclear 
which genetic markers determine patient symptoms, 
need for therapy and outcome.
Pain is a frequent problem in IBD, affecting approxi-
mately 70% of patients and it remains a long-stand-
ing problem for every second patient [6]. It is most 
frequently located in the abdomen and associated with a 
reduced quality of life (QoL) [7]. The severity of abdomi-
nal pain is an integral marker of many scales rating IBD 
disease activity, including the modified Truelove and 
Witts disease activity index (MTWAI) for UC [8] and the 
Crohn’s disease activity index (CDAI) [9] or PRO-2 [10] 
for CD. Abdominal pain is most severe when acute intes-
tinal inflammation is present but many IBD patients with 
endoscopic remission continue to experience abdominal 
pain [6, 11].
Abdominal pain in the absence of active inflammation 
is also characteristic for irritable bowel syndrome (IBS). 
IBS is a functional gastrointestinal disorder (FGID) and 
defined by the Rome IV criteria as recurrent abdominal 
pain at least once a week over the last three months and 
two or more of the following criteria: relation to def-
ecation, association with changes in stool frequency or 
changes in stool form [12]. In a meta-analysis, IBS-like 
symptoms were reported by almost 40% of IBD patients 
in remission [13], compared to 20% in the general popu-
lation [14, 15].
Several SNPs have been analysed in the context of IBS 
in large GWAS and meta-analyses [16–20]. The role of 
these “IBS-SNPs” in IBS pathogenesis has not yet been 
fully understood. Since abdominal pain is the leading 
symptom in IBS, genetic mechanisms contributing to 
abdominal pain in IBS might also be relevant for levels of 
abdominal pain in IBD patients. A potential role of IBS-
SNPs on the level of pain in patients with IBD has not yet 
been investigated.
Even though IBD and IBS are fundamentally different 
conditions, some pathways of pathogenesis including 
alterations in gut permeability, microbiota, inflammation, 
enteric nervous system, gut brain axis and psychological 
factors are partially shared [21]. Moreover, stimulators 
for abdominal pain such as tension and strong contrac-
tions in the gut, cytokines and an increased sensitiv-
ity towards visceral stimuli are likely relevant in both 
conditions [21–26]. It is therefore reasonable to assume, 
that IBS-associated genetic polymorphisms will also be 
relevant in IBD. Since pain remains the clinical hallmark 
of IBS, we hypothesize that IBS-associated polymor-
phisms will impact on the level of pain in IBD.
In the Swiss IBD cohort study (SIBDC) extensive clini-
cal information and genetic information are available. 
The primary aim of this study is to test for a possible 
association of IBS-SNPs and the level of abdominal pain 
in patients with IBD. The second goal is to explore the 
effects of abdominal pain on the disease management.
Methods
Patients
The SIBDC has been collecting longitudinal data of IBD 
patients from all parts of Switzerland since 2006. Patients 
are followed up yearly, using both a physician and a 
patient questionnaire. The design and goals of the SIBDC 
have been described elsewhere [27].
DNA genotyping and selection of SNPs
In 2015, in a comprehensive effort, the genotype of 379 
SNPs was determined in all SIBDC patients consenting to 
genetic analysis provided sufficient biomaterial was avail-
able. Selected SNPs comprise genetic markers associated 
with IBD risk, smoking, primary sclerosing cholangitis, 
anxiety, depression and pain after a thorough literature 
search. Genotyping of the SIBDC-SNPs was performed 
by Matrix-Assisted Laser Desorption/Ionisation–Time 
of Flight Mass Spectrometry (MALDI-TOF–MS) based 
SNP genotyping [28]. The complete list of SNPs available 
in the SIBDC data base is provided as Additional file 2. 
Serotonin transporter gene (SERT) polymorphisms (S/S, 
L/S and L/L) associated with IBS [29, 30] could not be 
determined by MALDI-TOF–MS for technical reasons.
Our selection of SNPs was based on SNPs previously 
identified in three GWAS [16–18] and two systematic 
reviews [19, 20]. To account for the more stringent SNP 
selection in GWAS, we performed a sensitivity analy-
sis which excluded all SNPs not identified by GWAS. 16 
SNPs identified in the above-mentioned five studies were 
also present in the SIBDC database and were selected 
for further analysis. No linkage disequilibrium (LD) was 
detected between the 16 selected SNPs (not shown).
IBD disease characteristics, socio‑demographic 
and psychological measures
Clinical, epidemiological, socio-demographic and psy-
chosocial data were extracted in autumn 2015 from the 
SIBDC database. Patient characteristics include gender, 
age at diagnosis, disease duration, time interval between 
IBD diagnosis and SIBDC enrolment, ethnicity, smoking 
habits [31], education, marital status, physical activity, 
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alcohol consumption, initial disease location and extent 
of disease, family history of IBD and extraintestinal mani-
festations (EIM). To assess mental health the hospital 
anxiety and depression scale (HADS) was used.
The primary endpoint of our study was maximal 
abdominal pain, assessed with the abdominal pain item 
from the CDAI for CD patients and the MTWAI for UC 
patients, respectively. Both scores distinguish four lev-
els of abdominal pain intensity: none, mild, moderate 
and severe. We selected the highest reported pain score 
(i.e. maximum abdominal pain) over the entire observa-
tion period. We favoured maximal abdominal pain since 
it is probably the measure closest associated with the 
main interest of our study: pain typical for IBD during a 
flare. During a flare, contacts to the health system is fre-
quent and the likelihood of an assessment for SIBDC is 
high. During these episodes, the highest pain levels are 
expected. Using maximal abdominal therefore maximises 
the chances to focus the assessment on pain due to acute 
inflammation. Moreover, maximal abdominal pain has 
been identified in a previous study as having the strong-
est impact on quality of life [32].
We also used median abdominal pain (i.e. median of all 
reported abdominal pain values over time) as a second-
ary readout in a sensitivity analysis. This measure likely 
integrates assessments during a flare as well as during 
remission. During remission, abdominal pain might be 
absent (in the absence of an inflammatory stimulus) or 
due to post-inflammatory IBS, which is not the focus of 
our study. In further sensitivity analyses, we also tested 
pain ever (moderate or severe vs. none or mild abdomi-
nal pain) as outcomes. To assess disease activity, we cal-
culated CDAI for CD and MTWAI for UC, according to 
SIBDC follow-up questionnaires.
For the number of physician contacts we calculated all 
visits to the primary care physician, gastroenterologist, 
hospital ambulatories and other doctors, starting three 
months before enrolment until data extraction.
The overall number of medical examinations (abdomi-
nal ultrasound, X-rays, CT-scan, MRI, colonoscopies) 
was used to characterize the vigour of diagnostic efforts. 
In an additional analysis, the overall number of medical 
examinations was adjusted for the number of visits.
As a simple summary measure for medical treat-
ments, we added the number of medical therapies ever 
used during the observation period in each patient. The 
following six classes of drugs were considered: (1) oral/
local prednisone or budesonide, (2) purine analogues 
(azathioprine, mercaptopurine), (3) sulfasalazine and 
oral/local 5-amino salicylic acid, (4) methotrexate, (5) 
TNF-inhibitors (infliximab, adalimumab, certolizumab) 
and (6) calcineurin inhibitors (cyclosporine, tacroli-
mus). No SIBDC patient had received vedolizumab 
or golimumab at time of data extraction. Addition-
ally, the use of TNF-inhibitors (yes or no) was analysed 
separately.
To calculate the duration of hospitalisation, all weeks 
spent hospitalised, from 12  months prior to enrolment 
until data extraction, were summarized. Endpoints for 
the quality of life were the inflammatory disease ques-
tionnaire (IBDQ) [33, 34] and the Short Form 36 Health 
Survey (SF-36) [35, 36].
Statistical analysis
Data were imported into the statistical program R ver-
sion 3.3.3 [37]. To assess the relationship between IBS-
associated SNPs and the endpoint of interest we first 
screened for an association of genotype and endpoint 
using univariate regression. For the multivariate analy-
sis, we performed step-wise model selection, consider-
ing disease characteristics, demographic features and 
psychosocial factors as predictors. Parameters were sys-
tematically eliminated by comparing models using the 
Akaike information criterion (AIC). AIC is a measure 
for the goodness-of-fit of a given model that takes model 
complexity into account with a preference for models 
with a lower number of parameters. We then included 
SNPs and covariates in a multivariate analysis of vari-
ance (ANOVA) model for prediction of our endpoints of 
interest. We performed model-based t-tests (contrasts) 
to assess individual associations between SNPs and end-
points while controlling for covariates. We used Bonfer-
roni and Benjamini–Hochberg correction [38] to correct 
for multiple testing. A corrected p-value (q) < 0.1 was 
considered significant.
Results
Study population and genetic information
For our analysis, clinical, epidemiological and genetic 
data of 2063 individuals with IBD were available. 1206 of 
those patients were diagnosed with CD and 857 with UC. 
Table 1 provides an overview of the study population; our 
study population comprises patients with mild, moderate 
and severe disease. The collected data of up to nine years 
of follow-up was analysed.
Selection of IBS‑associated SNPs
In the SIBDC data base, data relating to 379 SNPs 
are available (Additional file  2). IBS genetics has been 
assessed in three GWAS and two meta-analysis [16–20]. 
Of all SNPs identified in these studies, 16 SNPs associ-
ated with IBS were also present in the SIBDC data base 
(Table 2).
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Association of maximal abdominal pain 
with IBS‑associated SNPs
We tested the 16 IBS-associated SNPs (Table  2) for 
effects on our primary endpoint maximal abdominal 
pain. In a univariate analysis (Additional file 1: Table S1), 
rs4663866 (close to the HES6 gene) was strongly asso-
ciated with maximal abdominal pain in UC patients 
(P = 0.005). This association remained significant (q < 0.1) 
Table 1 Basic data and disease characteristics
Statistical analysis: t-test, Fisher’s exact test, Chi-squared test
n number, sd standard deviation
Overall CD UC
n = 2063 n = 1206 n = 857
Basic epidemiological and sociodemographic characteristics
Sex: Female; n (%) 1007 (48.8) 621 (51.5) 386 (45.0)
Age at diagnosis, median (sd) 31.2 (13.6) 29.9 (13.5) 33.0 (13.5)
Age at enrolment (years) 41.0 (14.7) 40.5 (15) 41.8 (14.3)
Disease duration (years) 14.6 (9.9) 15.4 (10.5) 13.4 (9.1)
Duration between diagnosis and enrolment (years) 9.9 (9.5) 10.6 (10) 8.76 (8.70)
Caucasian; n (%) 0.8 (0.4) 0.8 (0.4) 0.8 (0.4)
Higher education; n (%) 447 (27.1) 237 (25.2) 210 (29.7)
Swiss citizenship; n (%) 1271 (79.9) 732 (80.1) 539 (79.7)
Married; n (%) 779 (48.1) 404 (43.8) 375 (54.0)
Low physical activity (%) 652 (40.9) 406 (44.8) 246 (35.9)
Ever smoke; n (%) 955 (46.3) 698 (57.9) 257 (30.0)
Alcohol: rarely or never; n (%) 938 (57.0) 559 (59.4) 379 (53.7)
Alcohol: frequent (once a day); n (%) 111 (6.7) 73 (7.8) 38 (5.4)
Family history of CD; n (%) 172 (8.9) 143 (12.7) 29 (3.6)
Family history of UC; n (%) 110 (5.7) 37 (3.3) 73 (9.2)
Disease characteristics
Disease localisation CD
 Upper gastrointestinal tract 11 (0.9)
 Ileal 266 (22.1)
 Ileocolonic 572 (47.4)
 Colonic 263 (21.8)
Disease localisation UC
 Proctitis 134 (15.6)
 Left-sided colitis 286 (33.3)
 Pancolitis 355 (41.3)
Extraintestinal manifestations, any; n (%) 1181 (57.2) 738 (61.2) 443 (51.6)
Extraintestinal manifestation: arthritis/arthralgia; n (%) 984 (47.7) 636 (52.7) 348 (40.6)
Fistula in CD; n (%) 0.4 (0.48)
Fistula surgery in CD; n (%) 321 (26.6)
Patients with diarrhoea; n (%) 1378 (66.7) 820 (68) 558 (65)
Abdominal mass in CD; n (%) 507 (42)
Abdominal tenderness in UC; n (%) 349 (40.7)
Nightly diarrhoea in UC; n (%) 296 (34.5)
Blood in stool in UC; n (%) 448 (52.2)
Stool incontinence in UC; n (%) 157 (18.3)
Abdominal mass in CD; n (%) 507 (42)
Abdominal tenderness in UC; n (%) 349 (40.7)
Nightly diarrhoea in UC; n (%) 296 (34.5)
Blood in stool in UC; n (%) 448 (52.2)
Stool incontinence in UC; n (%) 157 (18.3)
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after the false-discovery rate was controlled by the Ben-
jamini–Hochberg procedure (q < 0.09, Fig. 1a). The rela-
tionship of maximal abdominal pain with rs4663866 
genotype CA/CC compared to AA remained significant 
in a multivariate ANOVA analysis controlling for covari-
ates (P = 0.037).
Our analysis also showed a significant univariate asso-
ciation between rs1042713 (ADRB2 gene, allele GG 
and AG; P = 0.012, q = 0.09) and the maximal abdomi-
nal pain levels in UC patients (Fig.  1b). This associa-
tion also remained significant in a multivariate ANOVA 
test (P = 0.044). Details of the difference in outcome 
according to the genotype (contrast in pain level) of 
rs4663866 and rs1042713 are shown in Table 3.
In a sensitivity analysis, we restricted our analysis to 
SNPs for which the association with IBS was identified by 
a GWAS. Since rs1042713 was not identified in a GWAS, 
such a stringent SNP selection would limit our results to 
rs4663866.
In additional sensitivity analyses, we also tested the 
association of median abdominal pain (instead of maxi-
mal abdominal pain) and the binary variable pain level 
(no or mild pain versus moderate or severe pain) with 
the selected SNPs. This yielded in similar results for 
Table 2 Analysed single-nucleotide polymorphisms
a A1: major allele, A2: minor allele
Name A1A2a Associated gene Chromosome Reference
rs1062613 CT 5-HT3A (5-hydroxytryptamine receptor 3E) 11 [20]
rs12702514 CT KDELR2 (ER lumen protein retaining receptor 2) 7 [16]
rs1800795 GC Il6 (Interleukin 6) 7 [19, 20]
rs324420 CA FAAH (Fatty acid amide hydrolase) 1 [20]
rs4663866 AC HES6 (Hes family bHLH transcription factor 6) 2 [16]
rs1042173 AC SLC64A (Solute carrier family 6) 17 [20]
rs1042713 GA ADRB2 (Beta-2-adrenergic receptor) 5 [20]
rs110402 GA CRHR1 (Corticotropin-releasing hormone receptor 1) 17 [20]
rs2020936 AG SLC64A (Solute carrier family 6) 17 [20]
rs242924 TG CRHR1 (Corticotropin-releasing hormone receptor 1) 17 [20]
rs3779250 CT CRHR1 (Corticotropin-releasing hormone receptor 2) 7 [20]
rs4680 GA COMT (Catechol-O-methyltransferase) 22 [20]
rs6269 AG COMT (Catechol-O-methyltransferase) 22 [20]
rs6311 CT HTR2A (5-hydroxytryptamine receptor 2A) 13 [20]
rs7432532 AC SCN5A (sodium voltage-gated channel alpha subunit 5) 3 [16]
rs2243250 CT IL4 (Interleukin 4) 5 [16, 19, 20]
a b
Fig. 1 Impact of IBS-associated SNPs on abdominal pain levels in patients with UC. Pain levels according to allele status of a rs4663866 and b 
rs1042713. Statistical analysis: univariate linear regression analysis 
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rs4663866 (median pain: P = 0.001, pain level: P = 0.011) 
but showed no significance for rs1042713 (median pain: 
P = 0.657, pain level: P = 0.089).
The univariate analysis of the selected SNPs with maxi-
mal abdominal pain in patients with CD showed nominal 
significance for four SNPs (rs1062613, rs3779250, rs4680 
and rs6311), which was lost after applying the Benja-
mini–Hochberg correction (q > 0.1) (Additional file  1: 
Table S1).
Effects of abdominal pain on disease management in IBD 
patients
The degree of abdominal pain was strongly associated 
with the management of IBD patients in a univariate 
analysis. Patients with severe pain had more clinical vis-
its, more examinations, a higher number of medical ther-
apies and spent more weeks hospitalised (Figs. 2, 3).
In a multivariate analysis controlling for confounders, 
medical management remained strongly associated with 
pain in CD (Fig. 4a) but less in UC patients (Fig. 4b). The 
level of abdominal pain in CD patients was associated 
with the number of visits during the observation period 
(incidence rate ratio (IRR) 1.14, P < 2 × 10–16; Additional 
file 1: Table S2). However, in the UC cohort no such rela-
tionship was detectable.
Maximal abdominal pain was also an independ-
ent and highly significant predictor for the number of 
examinations (IRR 1.16, P = 4.2 × 10–4 for UC; IRR 1.29, 
P = 1.8 × 10–18 for CD; Additional file 1: Table S3). How-
ever, other clinical variables including ethnicity, depres-
sion and EIM were also associated with the number of 
examinations. When the number of examinations was 
adjusted for the number of visits, maximal abdominal 
pain was no longer a significant predictor in UC patients, 
whereas in the CD cohort the association remained 
robust (IRR 1.10, P = 0.24 for UC; IRR 1.17, P = 0.007 for 
CD).
In a simplified assessment of the number of medical 
therapies in IBD patients, we considered six classes of 
drugs (see methods). For patients with UC and CD, in a 
univariate analysis, individuals with a higher degree of 
abdominal pain had been exposed to a higher number of 
different treatments (P < 2.0 × 10–16 for UC, P < 2.0 × 10–
16 for CD, Figs. 2c, 3c). However, in a multivariate analy-
sis, maximal pain remained an independent predictor for 
the number of therapies only in CD (IRR 1.06, P = 0.023; 
Additional file 1: Table S4), but not in UC. In a sub-analy-
sis, maximal abdominal pain showed a significant associ-
ation with the use of TNF-inhibitors only in CD patients 
(odds ratio, OR 1.29, P = 0.012), but not in UC patients 
(data not shown).
Finally, after controlling for confounders maximal pain 
remained a predictor for hospitalisation weeks only in 
CD (IRR 1.12, P = 0.001; Additional file 1: Table S5), but 
not in UC.
IBS‑associated SNPs do not influence disease course 
or management of IBD patients
When IBS-associated SNPs were tested as predictors for 
clinical endpoints including disease activity, number of 
visits, examinations, hospitalisation weeks, medical ther-
apies and TNF-inhibitor usage, no significant association 
robust to Bonferroni or Benjamini–Hochberg correction 
could be identified (data not shown).
Discussion
We used data of 2063 patients from the Swiss IBD cohort 
study to analyse pain in IBD patients. The risk alleles of 
two IBS-associated SNPs increased maximal pain inten-
sity experienced by UC but not CD patients. IBD patients 
frequently experience abdominal pain; however, in UC 
patients pain did not significantly influence management 
of IBD after controlling for confounders. In contrast, in 
CD patients, pain was associated with a higher number of 
physician contacts, examinations, medical therapies and 
hospitalisation weeks in a multivariate analysis. Both IBS-
associated SNPs did not influence patient management.
Pain in IBD might be caused by inflammatory and 
non-inflammatory pathways. The genetic risk for IBD is 
mediated by a number of genetic regions [2–4]. However, 
symptoms of IBD might also be shaped by additional 
genetic regions associated with IBS, since some path-
ways of the pathogenesis of both conditions are shared 
[21–26]. Our analysis suggests for a role of rs4663866 
and rs1042713 in mediating the level of pain experienced 
by IBD patients. Of note, our study does not distinguish 
between pain due to inflammatory and non-inflamma-
tory conditions. Future studies need to demonstrate 
whether these genetic polymorphisms affect patient 
Table 3 Significant single-nucleotide polymorphisms
Difference in outcome according to respective genotype and outcome. Reading example: our model predicts that patients with AA status at the rs4663866 loci have, 
on average, 0.17 lower maximal abdominal pain than those patients with CA/CC status at the rs4663866 loci. Statistical analysis: model-based t-test (contrasts)
SNP Outcome Contrast Slope estimate Lower 95% CI Upper 95% CI P‑value
rs4663866 (AA – CA/CC) Maximal abdominal pain − 0.17 0.082 − 0.33 − 0.010 0.037
rs1042713 (AA – AG—GG) Maximal abdominal pain − 0.18 0.088 0.35 − 0.005 0.044
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perception of inflammatory pain and/ or patient predis-
position to develop post-inflammatory IBS (IBD-IBS).
SNP rs1042713 is located on the ADRB2 gene which 
encodes the beta-2-adrenergic receptor. This recep-
tor plays an important role in pain signalling cascades 
[39, 40] and polymorphisms in rs1042713 affected 
agonist-induced receptor downregulation in  vitro [41]. 
Rs1042713 has been associated with pain, consultations 
and hospitalisations in sickle cell disease [42, 43], tem-
poromandibular pain [44], fibromyalgia [45] and chronic 
widespread pain [46].
The second SNP associated with abdominal pain, 
rs4663866, was identified in a GWAS for IBS [16]. 
rs4663866 was associated with the risk for IBS with 
a b
c d
Fig. 2 Effect of abdominal pain on disease management in patients with UC. Impact of pain on a number of visits, b number of examinations 
(ultrasound, endoscopy, X-ray, MRI, CT-scan), c cumulative number of drug classes prescribed and d number of weeks spent in hospital. Statistical 
analysis: univariate linear regression analysis 
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nominal but not genome-wide significance (P = 5 × 10–6). 
SNP rs4663866 is located near the transcription factor 
HES6 gene but no studies addressing rs4663866 func-
tion could be found in literature and mechanistic aspects 
remain unclear.
We would like to emphasise that testing for post-
inflammatory IBS in our study has not been possible 
for two reasons: First, Rome IV criteria for our patients 
were not available, preventing a formal diagnosis of IBS 
in our IBD cohort. Second, the inflammatory state (level 
of inflammation) has not been rigorously tested in our 
patients at the time of pain assessment.
In our study, abdominal pain was a crucial predictor 
for the intensity of disease management in CD patients. 
Maximal abdominal pain was strongly associated with 
the number of visits and investigations, TNF-inhibitor 
a b
c d
Fig. 3 Effect of abdominal pain on disease management in patients with CD. Impact of pain on a number of visits, b number of examinations 
(ultrasound, endoscopy, X-ray, MRI, CT-scan), c cumulative number of drug classes prescribed and d number of weeks spent in hospital. Statistical 
analysis: univariate linear regression analysis 
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usage and overall medical therapies as well as the 
length of time spent hospitalised. In other studies, 
patient management has also been associated with 
measures different from acute bowel inflammation: In a 
longitudinal study, IBS like symptoms in IBD increased 
the number of clinical visits and examinations during 
a follow up period of more than 2 years [47]. Further-
more, a recent large cross-sectional study reported an 
association between IBS-like symptoms and the use of 
narcotics, clinical visits and the use of some medication 
after controlling for a limited number of confounders 
[48].
In our study, pain influenced clinical management in 
CD but only to a much lower degree in UC. A poten-
tial explanation could be the easier clinical assessment 
of disease activity in UC patients. The rectum is uni-
formly affected in UC and disease activity directly 
correlates with the number of bowel movements and 
bloody diarrhoea. The partial Mayo score (consist-
ing of stool frequency, frequency of bloody stools and 
physician’s global assessment) is an accepted and vali-
dated endpoint in clinical studies of UC [49]. Of note, 
none of the considered IBS-SNPs were associated 
with IBD management. Therefore, physicians seem to 
rely on non-ambiguous signs of intestinal inflamma-
tion for decisions and genetic changes mediating pain 
levels might not significantly influence the clinical 
management.
In contrast, in CD, assessment of disease activity is 
complex and inflammation especially in the small intes-
tine will not necessarily result in non-ambiguous symp-
toms, requiring usage of “softer” parameters such as the 
intensity of abdominal pain for treatment decisions.
Besides pain, our study also identified well-known pre-
dictors of severe disease contributing to more intense 
disease management. EIM were uniformly associated 
with all endpoints of disease management in both, UC 
and CD. While abdominal pain was the single symptom 
most consistently associated with disease management 
in CD, in UC, the severity of diarrhoea predicted intense 
management better. Other clinical markers of disease 
activity such as bloody diarrhoea, abdominal mass and 
incontinence influenced some but not all outcomes.
Our study has several strengths and limitations. To the 
best of our knowledge, this study is the first to analyse 
the association between abdominal pain, SNPs previ-
ously analysed in the context of IBS and management and 
disease course in IBD patients. Due to the extensive data 
of our cohort, we were able to test and control for many 
possible epidemiological, sociodemographic and clinical 
confounders. Limitations include lack of testing for Rome 
IV criteria (see above). Also, the number of IBS-related 
SNPs tested in the Swiss IBD cohort is limited and not all 
SNPs identified by GWAS and systematic reviews were 
available. If selection of SNPs would be limited to SNPs 
with an association to IBS identified by a GWAS, only 
rs4663866 would remain. For instance, none of the SNPs 
tested were associated with pain in CD and it is possible 
that pain in CD is mediated by other SNPs. Our study 
should therefore be considered as pilot study and addi-
tional analyses with more SNPs are warranted. Further, 
effects of rs1042713 and rs4663866 should be confirmed 
in an independent cohort. No validated pain question-
naires (such as the McGill Pain Questionnaire [50]) could 
be used because these scores had not been collected in 
the SIBDC. A questionnaire dedicated to the experience 
of pain had been used only once in the SIBDC [6] and was 
filled only by a subset of patients. Therefore, we preferred 
b
a
Fig. 4 Abdominal pain levels strongly influence patient 
management in CD but not in UC patients. Forrest plot for the 
effect of abdominal pain on the indicated endpoints for a CD, b UC. 
Statistical analysis: multivariate logistic or Poisson regression models. 
Nominal associations: *P < 0.05, **P < 0.01, ***P < 0.001; Bonferroni 
corrected associations for confounders within the respective models: 
#P < 0.05, ##P < 0.01, ###P < 0.001
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to use the pain items in the CDAI and the MTWAI 
which were repeatedly acquired. The individual percep-
tion of pain is based on complex physical mechanisms 
depending on various psychosocial parameters [51] and 
ultimately remains a highly subjective experience of an 
individual. Taking this into account, the pain items of the 
CDAI and the MTWAI might only partially reflect the 
level of abdominal pain experienced by patients as they 
are filled out by physicians, based on patient’s reports.
Conclusions
Our study shows an association between pain levels in 
UC patients and IBS-associated SNPs, providing genetic 
evidence for an overlap of some disease mechanisms 
in IBD and IBS. We did not find an significant associa-
tion between abdominal pain and patient management 
in patients with UC. However, in CD patients, pain was 
a strong predictor for intense patient management with 
regard to clinical visits, investigations and medical thera-
pies, indicating that physicians use pain levels as a surro-
gate for disease activity in CD.
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